Valuation: Gilead Sciences, Inc.

Market Cap 19TCr 3,20500Cr 16TCr 15TCr 14TCr 26TCr 17,84600Cr 26TCr 1,82900Cr 71TCr 9,07600Cr 70TCr 68TCr 29,19500Cr P/E 2026 *
-45.4x
P/E 2027 * 18.7x
Enterprise Value 20TCr 3,49300Cr 18TCr 17TCr 15TCr 28TCr 19,45200Cr 29TCr 1,99400Cr 77TCr 9,89200Cr 76TCr 75TCr 31,82200Cr EV / Sales 2026 *
6.61x
EV / Sales 2027 * 5.97x
Free-Float
99.88%
Yield 2026 *
2.19%
Yield 2027 * 2.23%
18/09 Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% MT
17/09 Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing MT
16/09 Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited CI
16/09 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
15/09 Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean CI
15/09 Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
15/09 Gilead Sciences Expands Lenacapavir Access to 14 Countries MT
15/09 Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean RE
10/09 Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
10/09 HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating MT
09/09 Gilead Sciences, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 11:00 AM
09/09 Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead MT
09/09 Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead DJ
1 day-1.08%
Current month-0.68%
1 month+2.72%
3 months+15.87%
6 months-1.83%
Current year+10.39%
1 month 2,453.18
Extreme 2453.18
2,553.46
Current year 2,116
Extreme 2116
2,618.71
1 year 2,025.32
Extreme 2025.32
2,618.71
3 years 1,046.71
Extreme 1046.71
2,618.71
5 years 1,046.71
Extreme 1046.71
2,618.71
10 years 1,046.71
Extreme 1046.71
2,618.71
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%0.00% - - 19TCr
+0.04%+3.34%+53.32%+100.52% 1,02800Cr
-0.09%+1.66%+53.24%+66.45% 65TCr
-0.02%+2.66%+18.65%+71.97% 47TCr
-1.22%+3.66%+36.44%+38.32% 35TCr
-0.79%+2.73%+19.03%+25.08% 27TCr
+0.58%+6.76%+11.13%+16.52% 26TCr
+1.55%+2.20%+35.12%+45.91% 21TCr
+0.79%+1.84%-28.27%-56.71% 19TCr
-0.52%+4.45%+31.57%+98.11% 19TCr
Average -0.08%+3.26%+25.58%+45.13% 40.02TCr
Weighted average by Cap. -0.09%+3.09%+35.12%+61.45%

Financials

2026 *2027 *
Net sales 3.07TCr 53TCr 2.67TCr 2.52TCr 2.29TCr 4.29TCr 2,94400Cr 4.31TCr 30TCr 12TCr 1,49700Cr 12TCr 11TCr 4,81600Cr 3.27TCr 56TCr 2.85TCr 2.69TCr 2.44TCr 4.57TCr 3,13400Cr 4.59TCr 32TCr 12TCr 1,59400Cr 12TCr 12TCr 5,12600Cr
Net income -427.47Cr -7.36TCr -372.17Cr -351.3Cr -319.17Cr -597.9Cr -41TCr -600.63Cr -4.2TCr -1.62TCr -21TCr -1.61TCr -1.57TCr -67TCr 1.03TCr 18TCr 894.57Cr 844.41Cr 767.19Cr 1.44TCr 99TCr 1.44TCr 10TCr 3.9TCr 50TCr 3.86TCr 3.77TCr 1,61200Cr
Net Debt 1.67TCr 29TCr 1.46TCr 1.38TCr 1.25TCr 2.34TCr 1,60600Cr 2.35TCr 16TCr 6.36TCr 82TCr 6.29TCr 6.15TCr 2,62700Cr 912.45Cr 16TCr 794.4Cr 749.86Cr 681.29Cr 1.28TCr 87TCr 1.28TCr 8.97TCr 3.46TCr 44TCr 3.43TCr 3.35TCr 1,43100Cr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
150.11USD
Average target price
158.15USD
Spread / Average Target
+5.35%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!